Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders

Patent metadata

Field	Value
Publication number	US-2016199446-A1
Application number	US-201615000988-A
Country	US
Kind code	A1
Filing date	Jan 19, 2016
Priority date	Jul 14, 2008
Publication date	Jul 14, 2016
Grant date	—

Abstract

Disclosed herein are compositions and methods for the treatment of otic disorders with anti-apoptotic agent or pro-apoptotic agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

First claim

1 - 19 . (canceled)

20 . A method of ameliorating or reducing the occurrence of inner ear tinnitus induced by acoustic trauma, presbycusis, exposure to ototoxic drugs, hearing loss, otic infection, otic inflammation, or otic tumor in a human in need thereof, the method comprising administering to the human a pharmaceutical composition comprising a therapeutically effective amount of a peptide inhibitor of c-Jun N-terminal kinase (JNK) or a pharmaceutically acceptable salt thereof.

21 . The method of claim 20 , wherein the peptide inhibitor comprises D-JNKI-1.

22 . The method of claim 20 , wherein the peptide inhibitor comprises or consists of the sequence of (D)-hJIP 175-157 -DPro-DPro-(D)-HIV-TAT 57-48 .

23 . The method of claim 20 , wherein the pharmaceutical composition is administered to the human following onset of the acoustic trauma, presbycusis, exposure to ototoxic drugs, hearing loss, otic infection, otic inflammation, or otic tumor.

24 . The method of claim 20 , wherein the human has or is diagnosed with hearing loss of at least 30 dB developing within 1 month of onset of the acoustic trauma, presbycusis, exposure to ototoxic drugs, hearing loss, otic infection, otic inflammation, or otic tumor.

25 . The method of claim 20 , wherein the pharmaceutical composition is administered topically via the round window membrane or the oval window membrane to the inner ear.

26 . The method of claim 20 , wherein the pharmaceutical composition is administered by an intratympanic injection.

27 . The method of claim 20 , wherein the pharmaceutical composition is delivered to the middle ear.

28 . The method of claim 20 , wherein the pharmaceutical composition is a gel.

29 . The method of claim 20 , wherein the pharmaceutical composition comprises about 0.5% to about 1.0% of a viscosity enhancing agent, wherein the viscosity enhancing agent is sodium hyaluronate or hyaluronic acid.

30 . The method of claim 20 , wherein the pharmaceutical composition comprises a phosphate buffer which buffers the pH of the composition to 6.0 to 7.6.

31 . The method of claim 20 , wherein the therapeutically effective amount of the peptide inhibitor is about 0.02 mg to about 50 mg.

32 . The method of claim 20 , wherein the therapeutically effective amount of the peptide inhibitor is about 0.02 mg to about 1 mg.

33 . The method of claim 20 , wherein the therapeutically effective amount of the peptide inhibitor is administered in multiple doses.

Assignees

• Otonomy Inc
• Univ California

Inventors

• Lichter Jay
• Trammel Andrew M
• Piu Fabrice
• Ye Qiang
• Scaife Michael Christopher
• Vollrath Benedikt
• Duron Sergio G
• Dellamary Luis A
• Lebel Carl
• Harris Jeffrey P

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/16

  Otologicals · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K38/162

  from virus · CPC title

• A61K38/1709 Primary

  from mammals · CPC title